Skip to main content
SpringerLink
Log in

Ramucirumab plus erlotinib tolerable despite AEs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Nadal E, et al. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability Drug Safety : 20 Dec 2021. Available from: URL: https://doi.org/10.1007/s40264-021-01127-2

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ramucirumab plus erlotinib tolerable despite AEs. Reactions Weekly 1888, 12 (2022). https://doi.org/10.1007/s40278-022-08354-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-08354-8

Search

Navigation